| Study | Case | Baseline | Week 24 |
| A: Gorman Diplopia Score in patients who received teprotumumab | |||
| 3 | 1 | 3 | 0 |
| 3 | 2 | 3 | 0 |
| 3 | 3 | 1 | 1 |
| 2 | 4 | 3 | 1 |
| 2 | 5 | 3 | 1 |
| 2 | 6 | 3 | 2 |
| 2 | 7 | 3 | 0 |
| 2 | 8 | 2 | 0 |
| 2 | 9 | 3 | 0 |
| 2 | 10 | 1 | 2 |
| Mean | 2.3 | 0.7 | |
| SD | 1.1 | 0.8 | |
| B: Gorman diplopia score in patients who received Placebo | |||
| Phase 3 | 1 | 0 | 2 |
| Phase 3 | 2 | 2 | 2 |
| Phase 3 | 3 | 3 | 3 |
| Phase 3 | 4 | 0 | 0 |
| Phase 3 | 5 | 3 | 3 |
| Phase 3 | 6 | 3 | 2 |
| Phase 2 | 7 | 1 | 3 |
| Phase 2 | 8 | 3 | 3 |
| Phase 2 | 9 | 0 | 2 |
| Phase 2 | 10 | 0 | 0 |
| Phase 2 | 11 | 1 | 1 |
| Phase 2 | 12 | 1 | 3 |
| Mean | 1.4 | 2 | |
| SD | 1.3 | 1.1 | |